SAB Biotherapeutics (NASDAQ:SABSW – Get Free Report) is expected to be issuing its resultson Thursday, March 26th. Analysts expect the company to announce earnings of ($0.2138) per share for the quarter.
SAB Biotherapeutics Stock Up 4.0%
Shares of SABSW stock opened at $0.03 on Wednesday. SAB Biotherapeutics has a 1-year low of $0.02 and a 1-year high of $0.18. The stock has a 50 day simple moving average of $0.03 and a 200-day simple moving average of $0.03.
SAB Biotherapeutics Company Profile
SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company specializing in the development of fully human polyclonal antibody therapeutics. The company’s core technology, known as the Transchromosomic (Tc) Bovine platform, leverages genetically engineered cattle to produce large volumes of human antibodies in response to targeted antigens. These antibodies are designed to treat a range of infectious diseases and immunological disorders, offering a complementary approach to monoclonal antibodies and traditional vaccines.
The company’s lead programs focus on combating high-priority pathogens, including emerging coronaviruses and other viral threats.
Read More
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
